do-me/EUR-LEX huggingface dataset:
Non-opposition to a notified concentration (Case M.10079 — SARP/Suez RV Osis) (Text with EEA relevance) 2021/C 83/02
Date: 2021-03-04
Institutions: Directorate-General for Competition, European Commission
Subjects: Belgium, France, Luxembourg, economic concentration, maintenance, merger control, provision of services, public sanitation, water treatment








C_2021083EN.01000201.xml










12.3.2021   


EN


Official Journal of the European Union


C 83/2






Non-opposition to a notified concentration
(Case M.10079 — SARP/Suez RV Osis)
(Text with EEA relevance)
(2021/C 83/02)
On 4 March 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in French and will be made public after it is cleared of any business secrets it may contain. It will be available:






—


in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes.










—


in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10079. EUR-Lex is the online access to European law.






(1)  OJ L 24, 29.1.2004, p. 1.
Case T-132/20: Order of the General Court of 4 March 2021 — NEC OncoImmunity v EASME (Action for annulment — Framework Programme for Research and Innovation ‘Horizon 2020’ (2014-2020) — Grant agreement — Termination letter — Act coming within a purely contractual framework from which it is inseparable — Inadmissibility — Regulation (EU) No 1290/2013 — Loss of SME status)
Date: 2021-03-04
Institutions: General Court
Subjects: Framework Programme for Research and Development, admissibility, contract terms, eligibility criteria, equal treatment, principle of legal certainty, research and development, small and medium-sized enterprises, termination of a contract








C_2021163EN.01003202.xml










3.5.2021   


EN


Official Journal of the European Union


C 163/32






Order of the General Court of 4 March 2021 — NEC OncoImmunity v EASME
(Case T-132/20) (1)

(Action for annulment - Framework Programme for Research and Innovation ‘Horizon 2020’ (2014-2020) - Grant agreement - Termination letter - Act coming within a purely contractual framework from which it is inseparable - Inadmissibility - Regulation (EU) No 1290/2013 - Loss of SME status)
(2021/C 163/43)
Language of the case: English

Parties


Applicant: NEC OncoImmunity AS (Oslo, Norway) (represented by: T. Nordby, R. Bråthen and O. Brouwer, lawyers)

Defendant: Executive Agency for Small and Medium-sized Enterprises (represented by: G. Niddam and A. Galea, acting as Agents, and by D. Waelbroeck and A. Duron, lawyers)

Re:

Application primarily based on Article 263 TFEU seeking annulment of the decision allegedly contained in EASME's letter No Ares (2019) 7905893 of 23 December 2019 terminating the grant agreement concluded under the ‘Horizon 2020’ framework programme for research and innovation (2014-2020) and, in the alternative, an application based on Article 272 TFEU seeking a declaration that the terms of that agreement were breached.

Operative part of the order







1.


The action as dismissed as inadmissible.










2.


NEC OncoImmunity AS is ordered to pay the costs.






(1)  OJ C 161, 11.5.2020.